Interventions of Interest: The independent appraisal committee voted that currently available evidence is not adequate to demonstrate a net health benefit for lecanemab when compared to supportive care. Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if priced between $8,900 – $21,500 per year. Final Documents ICER’s […]
ICER produced a comprehensive white paper on diagnostic testing for Alzheimer’s disease that was presented to the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC). Date of review: January 2013 For questions, contact info@icer.org. Intervention of interest: Diagnostics for Alzheimer’s disease Final Documents Below you will find the final documents from the policy paper review […]
Interventions of Interest: During the public meeting, an independent appraisal committee voted unanimously (15-0) that the evidence was not adequate to demonstrate that aducanumab plus supportive care provides a net health benefit when compared to supportive care alone. In light of substantial uncertainty of patient benefit, policy recommendations call for: Date of Review: July 2021 For questions, please […]